Sign In
Buy FPI
$10.31
-0.0700 (-0.674%)
At Close: Jun 03, 2026
Why I Don't Invest In REIT ETFs
08:25am, Tuesday, 25'th Feb 2025
Passive beats active in most cases. REITs are an exception. I explain why I follow an active strategy when investing in REITs.
Farmland Partners Inc. (FPI) Q4 2024 Earnings Call Transcript
03:20pm, Thursday, 20'th Feb 2025
Farmland Partners Inc. (NYSE:FPI ) Q4 2024 Results Conference Call February 20, 2025 11:00 AM ET Company Participants Luca Fabbri - President and CEO Christine Garrison - General Counsel Paul Pittman
Farmland Partners Inc. Reports Full Year 2024 Results
04:05pm, Wednesday, 19'th Feb 2025
DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (“FPI” or the “Company”) today reported financial results for the year ended December 31, 2024. Selected Highlights During the year
Farmland Partners Inc. Announces Date for Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call
04:30pm, Thursday, 13'th Feb 2025
DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company”) today announced it will release its financial results for the fourth quarter and year ended December 31, 2024, after 5 p
Buy The Dip: High-Conviction High-Yields Getting Way Too Cheap
04:59pm, Monday, 10'th Feb 2025
Warren Buffett once offered sage advice on how to pick winning stocks. We have identified some of these types of stocks trading at compelling bargains. We share several high-conviction picks in this a
Buy Land, They Don't Make It Anymore: 3 'Dirt' Cheap Big Dividends And Buybacks
07:05am, Saturday, 01'st Feb 2025
Land has proven to be an excellent long-term risk-adjusted investment. Fortunately, there are numerous opportunities to buy it at a steep discount right now. I share three compelling opportunities, yi
Farmland Partners Announces Tax Treatment of 2024 Distributions
04:30pm, Friday, 31'st Jan 2025
DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company” or “FPI”) today announced the tax treatment of our 2024 common stock distributions, as summarized in the following ta
The State Of REITs: January 2025 Edition
11:19pm, Wednesday, 22'nd Jan 2025
The REIT sector took a beating in December with an average total return of -6.85% but still finished in the black for full year 2024 (+3.70%). Small cap (-5.98%) and mid cap REITs (-6.62%) outperforme
Farmland Partners: Diversification Benefits And An Improving Dividend Profile
04:01am, Saturday, 28'th Dec 2024
Data suggests that Farmland Partners Inc. offers diversification benefits with a weak correlation to major equity and real estate ETFs. The REIT's business model includes leasing agricultural land, se
Farmland Partners: AFFO Set To Benefit From Deleveraging In 2025
09:16am, Friday, 27'th Dec 2024
Farmland Partners executed two significant transactions in Q4 2024 producing proceeds of $308 million and exiting the Florida, South and North Carolina farmland markets. The transaction increases the
3 Big Dividends Backed By High-Quality Assets
03:06pm, Monday, 16'th Dec 2024
Avoid private equity and REITs offering unsustainable high yields; they often rely on risky investments or leverage, leading to potential capital destruction. We prefer to look at the cashflows first
Farmland Partners Declares $1.15 per Share Special Dividend After Strong Year
07:10am, Friday, 13'th Dec 2024
DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company” or “FPI”) today announced that its Board of Directors has declared a one-time dividend of $1.15 per share of common s
'Tis The Season For REIT Dividends
09:00am, Sunday, 01'st Dec 2024
U.S. equity markets climbed to fresh record-highs while benchmark interest rates dipped sharply, as investors parsed inflation data and deliberated the potential implementation and impacts of Trump Ad
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
08:01am, Monday, 11'th Nov 2024
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors
